explore -WSS

explore

author：Wikipedia 2025-09-27 10:04:59 - browse：319

Vertex Pharmaceuticals - sunset — Bill Sikes/AP

Vertex Pharmaceuticals has spent decades trying to develop molecules that reduce pain safely and potently, searching for success in a field its own executives have dubbed a graveyard for drug discovery. Detailed data published Wednesday lent support to that quest, with a pair of company-sponsored clinical trials showing an experimental non-opioid therapy reduced pain after surgery.

The drug, VX-548, blocks signals from pain-sensitive neurons before those electrical messages reach the brain. And in a pair of randomized trials, patients given a high dose of the oral medication after bunion surgery or abdominoplasty (a tummy tuck) reported less pain than those given a placebo. Those taking lower doses of the treatment showed no improvement compared to the placebo group, however.

While the pain reduction measured by these Phase 2 trials was statistically significant, it’s unclear how meaningful the drug’s benefits were to patients, with a commentary accompanying the study describing the treatment effect as “small.” But the study authors noted that participants on a high dose of VX-548 were less likely to prematurely stop their treatment because it wasn’t working than those on placebo or participants given a combination of two common painkillers, acetaminophen and hydrocodone.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Drug for rare kidney disease narrowly misses mark in clinical trial

WSS

Orangutan used medicinal plant to treat wound, first time ever seen

Cue Health's Covid

Experts study whether long Covid risk adds up with each reinfection

Key Senate committee drafts bipartisan bill to stem drug shortages

Medical student insurance fails on mental health care coverage

FDA panel to weigh approval of NurOwn, controversial ALS drug

hotspot

explore

hotspot

Activists slam private health insurers over coverage restrictions

How Vertex's cystic fibrosis drug is changing patients' lives

Bright Health sells Medicare Advantage business to Molina

Bird flu in milk supply is likely coming from asymptomatic cows

Medicare proposal to cover medical devices draws a mixed reaction

Medical bills so high, Medicare adding extra digits to claim forms

In age of alternative facts, a scholarly course on calling out crap

Cell therapy fails to slow type 1 diabetes, but safety is established

Sports medicine is finally prioritizing gender equality

Medical bills so high, Medicare adding extra digits to claim forms

Wikipedia

More tobacco lobbyists active in statehouses

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Readout LOUD podcast: possible new ALS drug, artificial wombs

Microbiome research is starting to find links to chronic diseases

Cholera vaccine supply gets boost as demand surges globally

entertainment

focus

focus

hotspot